Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast 2015

1
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)Pipeline Review, H2 2015
Published on October - 2015
2
.
Report Overview
About Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) Pipeline Review, H2
2015 Research Beam added report on Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP)
Pipeline Review, H2 2015. Summary Global
Markets Directs, Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) Pipeline
Review, H2 2015, provides an overview of the
Growth Hormone Deficiencies therapeutic
pipeline. This report provides comprehensive
information on the therapeutic development for
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP), complete with comparative analysis at
various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along
with latest updates, and featured news and press
releases. It also reviews key players involved in
the therapeutic development for Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP)
and special features on late-stage and
discontinued projects. Get Full Details On
http//www.researchbeam.com/atrial-fibrillation-pi
peline-review-h2-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis.  The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.  
4
.
Report Overview
Scope The report provides a snapshot of the
global therapeutic landscape of Chronic
Inflammatory Demyelinating Polyneuropathy
(CIDP) The report reviews key pipeline products
under drug profile section which includes,
product description, MoA and RD brief, licensing
and collaboration details other developmental
activities The report reviews key players
involved in the therapeutics development for
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP) and enlists all their major and minor
projects The report summarizes all the dormant
and discontinued pipeline projects A review of
the Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) products under development
by companies and universities/research institutes
based on information derived from company and
industry-specific sources Pipeline products
coverage based on various stages of development
ranging from pre-registration till discovery and
undisclosed stages A detailed assessment of
monotherapy and combination therapy pipeline
projects  
5
Report Overview
Reasons to buy Provides strategically significant
competitor information, analysis, and insights to
formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) Plan mergers and
acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) pipeline depth and focus of
Indication therapeutics Develop and design
in-licensing and out-licensing strategies by
identifying prospective partners with the most
attractive projects to enhance and expand
business potential and Scope Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline  
6
Table Of Contents
List of Tables 4List of Figures 4Introduction
5Global Markets Direct Report Coverage 5Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP)
Overview 6Therapeutics Development 7Pipeline
Products for Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) - Overview 7Pipeline
Products for Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) - Comparative Analysis
8Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) - Therapeutics under
Development by Companies 9Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) - Pipeline
Products Glance 10Late Stage Products
10Clinical Stage Products 11
7
Table Of Contents
Early Stage Products 12Unknown Stage Products
13Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) - Products under
Development by Companies 14Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) - Companies
Involved in Therapeutics Development 15Baxalta
Incorporated 15GeNeuro SA 16Mitsubishi Tanabe
Pharma Corporation 17Pfizer Inc. 18Teijin
Pharma Limited 19Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) -
Therapeutics Assessment 20
8
Table Of Contents
Assessment by Monotherapy Products 20Assessment
by Combination Products 21Assessment by Target
22Assessment by Mechanism of Action
24Assessment by Route of Administration
25Assessment by Molecule Type 27 Enquiry
about this report _at_ http//www.researchbeam.com/at
rial-fibrillation-pipeline-review-h2-2015-market/e
nquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/atrial-fibrillation-pi
peline-review-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com